Search results for "coinfection"

showing 10 items of 126 documents

Helicobacter pylori and epstein–barr co-infection in gastric disease

2017

The incidence of gastrointestinal diseases and in particular gastric cancer (GC) is high worldwide. Over the last few years, numerous studies have speculated that Helicobacter pylori (H. pylori) and Epstein-Barr virus (EBV) can be correlated with gastric cancerogenesis. Virulence factors of H. pylori can contribute to the variability of clinical outcomes: among the most important virulence factors is the pathogenicity island (CagPAI), vacA and oipA gene. EBV infection usually persists in B cells and induces an inflammatory reaction in cooperation with H. pylori. In Sicily, H. pylori and EBV infections are particularly prevalent, and to our knowledge no study has addressed this yet. The aim …

H. pylori EBV coinfection Italy gastric diseases.
researchProduct

Hepatitis delta virus (HDV) coinfection among patients with HBsAg positive cirrhosis. An analysis the MASTER-B cohort

2014

HBsAgCirrhosisHepatologybusiness.industryCohortGastroenterologyCoinfectionmedicinemedicine.diseasebusinessHepatitis delta virus HDVVirologyDigestive and Liver Disease
researchProduct

Critical reappraisal of risk factors for occurrence of hepatocellular carcinoma in patients with hepatitis C virus.

2011

More than one and half of current cases of hepatocellular carcinoma in the US, Europe, and Japan are attributable to hepatitis C virus (HCV) infection. HCV is also the primary cause of death in patients with HCV-related cirrhosis, with annual incidences of 0.5%-5% in Europe and 4%-10% in Asia. Screening is based on serum alpha-fetoprotein determination and liver ultrasound scan, but the sensitivity of the former is far less than optimal, and screening intervals are still poorly defined for the latter. Risk factors related to the host or environment, or both, appear to be more relevant than viral factors, such as HCV genotype, in determining disease progression to cirrhosis and cancer, and i…

Hepatitis B virushepatitis C virusmedicine.medical_specialtyCirrhosisHepatologybusiness.industryHepatitis C virusmedicine.medical_treatmentCancerReviewhepatocellular carcinomaLiver transplantationmedicine.diseasemedicine.disease_causeGastroenterologyLiver diseaseInternal medicineHepatocellular carcinomaImmunologymedicineCoinfectionbusinessHepatic medicine : evidence and research
researchProduct

Guía de tratamiento de la infección por virus de la hepatitis C. Asociación Española para el Estudio del Hígado (AEEH)

2018

Hepatitismedicine.medical_specialtyHepatologybusiness.industrymedicine.medical_treatmentGastroenterologySalvage therapyHepatitis CHepatitis BLiver transplantationmedicine.diseaseGastroenterology03 medical and health sciences0302 clinical medicinePharmacotherapy030220 oncology & carcinogenesisInternal medicinemedicineCoinfection030211 gastroenterology & hepatologybusinessGastroenterología y Hepatología
researchProduct

HCV/HBV coinfection: The dark side of DAAs treatment?

2016

HepatologyCoinfectionbusiness.industryHIV InfectionsHepatitis CHepatitis BHepatitis Bmedicine.diseaseAntiviral AgentsHepatitis CVirology03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesismedicineCoinfectionHumans030211 gastroenterology & hepatologybusinessLiver International
researchProduct

Frequent coinfection of cells explains functional in vivo complementation between cytomegalovirus variants in the multiply infected host.

2005

In contrast to many other virus infections, primary cytomegalovirus (CMV) infection does not fully protect against reinfection. Accordingly, clinical data have revealed a coexistence of multiple human CMV variants/ strains in individual patients. Notably, the phenomenon of multiple infection was found to correlate with increased virus load and severity of CMV disease. Although of obvious medical relevance, the mechanism underlying this correlation is unknown. A weak immune response in an individual could be responsible for a more severe disease and for multiple infections. Alternatively, synergistic contributions of variants that differ in their biological properties can lead to qualitative…

Human cytomegalovirusMuromegalovirusImmunologyPopulationGreen Fluorescent ProteinsBiologymedicine.disease_causeMicrobiologyHerpesviridaeVirusMiceViral ProteinsBetaherpesvirinaeVirologymedicineAnimalseducationLungeducation.field_of_studyMice Inbred BALB CIntegrasesVirulenceGenetic VariationInborn immunodeficiencyCytomegalovirusmedicine.diseasebiology.organism_classificationVirologyGenetic Diversity and EvolutionInsect ScienceImmunologyCytomegalovirus InfectionsCoinfectionNIH 3T3 CellsFemaleSpleenJournal of virology
researchProduct

From current status to optimization of HCV treatment: Recommendations from an expert panel

2016

Chronic hepatitis C virus (HCV) infection is a major public health problem at a global level, causing an enormous burden of hepatic and extra-hepatic morbidity and mortality. Treatment of chronic HCV (CHC) has been revolutionized in the last few years by the introduction of highly effective and well tolerated direct acting antiviral agents (DAAs) able to achieve >90% rates of sustained virological response (SVR) in many groups of patients, including those previously excluded from interferon-based regimens. For such reason interferon-free regimens are now the treatments of choice for all patients. Successful anti-HCV treatment can stop liver disease progression and can solve the HCV-relat…

Liver CirrhosisDirect-acting antiviral agentmedicine.medical_treatmentResistanceAntiviral therapy; Cirrhosis; Direct-acting antiviral agents; HCV; Hepatitis C; Liver transplantation; Resistance; Antiviral Agents; Carcinoma Hepatocellular; Coinfection; Drug Therapy Combination; HIV Infections; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Italy; Liver Cirrhosis; Liver Neoplasms; Practice Guidelines as Topic; Ribavirin; Societies Medical; Viral Load; Hepatology; GastroenterologyHIV InfectionsHepacivirusAntiviral therapy; Cirrhosis; Direct-acting antiviral agents; HCV; Hepatitis C; Liver transplantation; Resistance; Hepatology; GastroenterologyLiver transplantationAntiviral therapyLiver disease0302 clinical medicineHIV Infection030212 general & internal medicineChronicSocieties MedicalCoinfectionLiver NeoplasmsGastroenterologyHepatitis CViral LoadSettore MED/07 - Microbiologia e Microbiologia ClinicaHepatitis CItalyCirrhosisLiver NeoplasmCombinationPractice Guidelines as TopicHCV030211 gastroenterology & hepatologyDrug Therapy CombinationViral loadHumanAntiviral therapy; Cirrhosis; Direct-acting antiviral agents; HCV; Hepatitis C; Liver transplantation; Resistancemedicine.medical_specialtyCarcinoma HepatocellularLiver CirrhosiAlpha interferonAntiviral therapy; Cirrhosis; Direct-acting antiviral agents; HCV; Hepatitis C; Liver transplantation; Resistance; Antiviral Agents; Carcinoma Hepatocellular; Coinfection; Drug Therapy Combination; HIV Infections; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Italy; Liver Cirrhosis; Liver Neoplasms; Practice Guidelines as Topic; Ribavirin; Societies Medical; Viral LoadAntiviral Agents03 medical and health sciencesDrug TherapyMedicalInternal medicineRibavirinmedicineHumansIntensive care medicineAntiviral AgentCirrhosiHepaciviruLiver transplantationHepatologybusiness.industryPublic healthCarcinomaInterferon-alphaHepatocellularHepatologyHepatitis C Chronicmedicine.diseaseSurgeryPosition paperDirect-acting antiviral agentsSocietiesbusiness
researchProduct

Oral lichen planus, hepatitis C virus, and HIV: no association in a cohort study from an area of high hepatitis C virus endemicity

2004

Abstract Objectives We sought to assess the age-specific prevalence of oral lichen planus (OLP) in Mediterranean patients with chronic hepatitis C virus (HCV) and to evaluate the features of OLP in relation to sex, smoking, HCV genotype, HIV-1 coinfection, and antiviral treatments. Methods In all, 178 anti-HCV-positive adults (60 women and 118 men; age range 20-66 years) recruited from two cohorts (104 HIV-negative patients and 74 patients with HIV coinfection) underwent oral examination. Results Overall prevalence of OLP was 2.8% (5 of 178) (male/female ratio 0.2; odds ratio=0.119; 95% confidence interval=0.013-1.106), only among HIV-negative participants, always in the reticular pattern, …

Liver CirrhosisMaleHepacivirusHIV Infectionsclinical-featureComorbidityHepacivirusmedicine.disease_causeCohort Studieschemistry.chemical_compoundPrevalenceMedicineExtrahepatic manifestationbiologySmokingvirus diseasesMiddle AgedHepatitis CCoinfectionFemalegeneral-populationmedicine.drugAdultmedicine.medical_specialtyGenotypeHepatitis C virushuman-immunodeficiency-viruDermatologyHCV hyperendemic areaAntiviral AgentsFlaviviridaeAge Distributionstomatognathic systemInternal medicineHumansInterferon alfaAgedbusiness.industryRibavirinChronic active hepatitiOdds ratiomedicine.diseasebiology.organism_classificationstomatognathic diseaseschemistrypositive patientsImmunologynegative patientliver-diseaseOral lichen planusinterferon therapybusinessLichen Planus Oral
researchProduct

Non-invasive assessment of liver steatosis and fibrosis in HIV/HCV- and HCV- infected patients

2013

BACKGROUND: Conflicting data have been reported on the prevalence of liver steatosis, its risk factors and its relationship with fibrosis in patients with human immunodeficiency virus (HIV)/hepatitis C virus (HCV) co-infection or with HCV mono-infection. AIM: The study aims were to assess steatosis prevalence and its risk factors in both HCV groups. We also evaluated whether steatosis was linked with advanced fibrosis. Sixty-eight HIV/HCV co-infected and 69 HCV mono-infected patients were consecutively enrolled. They underwent liver ultrasonography and transient elastography. Bright liver echo-pattern was used to diagnose steatosis; advanced fibrosis was defined as liver stiffness ≥ 9.5 kPa…

Liver CirrhosisMaleHepatic steatosisTransient elastographySpecialties of internal medicineHIV Infectionsmedicine.disease_causeGastroenterologyRisk FactorsFibrosisPrevalenceFIB–4CoinfectionGeneral MedicineHepatitis CMiddle AgedItalyRC581-951Area Under CurveFIB-4Elasticity Imaging TechniquesFemaleLipodystrophyAdultmedicine.medical_specialtyHepatitis C virusLiver fibrosisHepatic steatosiWhite PeopleHIV/HCV co-infectionPredictive Value of TestsInternal medicinemedicineHumansChi-Square DistributionHepatologybusiness.industryLiver fibrosiHepatitis C Chronicmedicine.diseaseImpaired fasting glucoseFatty LiverLogistic ModelsROC CurveMultivariate AnalysisSteatosisMetabolic syndromeTransient elastographybusinessBiomarkersAnnals of Hepatology
researchProduct

Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis

2008

BACKGROUND: While the likelihood of developing hepatocellular carcinoma (HCC) in patients coinfected with both HBV and HCV is increased, the role of previous exposure to HBV as a risk factor associated with tumor occurrence in subjects with HCV-related cirrhosis has not been fully investigated. AIM: To assess whether serum anti-HBc positivity, as a marker of previous HBV exposure, is associated with HCC development in HCV-related positive, hepatitis B surface antigen (HBsAg) negative patients with cirrhosis treated with alfa-interferon (IFN) monotherapy. PATIENTS AND: A database including 883 consecutive patients (557 men, mean age 54.7 yr) with histologically METHODS: proven cirrhosis trea…

Liver CirrhosisMalePathologyCirrhosisAdult Antibodies; Viral; blood Carcinoma; Hepatocellular; blood/pathology/virology Cohort Studies Female Hepatitis B Core Antigens; immunology Hepatitis B virus; immunology Hepatitis C; blood/complications/pathology Humans Liver Cirrhosis; blood/etiology/pathology Liver Neoplasms; blood/pathology/virology Male Middle Aged Retrospective Studies Risk FactorsAntibodies ViralGastroenterologyanti HBcCohort StudiesimmunologyRisk FactorsHBVViralHCCCIRRHOSISLiver NeoplasmsGastroenterologyvirus diseasesHBV HCV COINFECTIONMiddle AgedHepatitis B Core AntigensHepatitis CAdult; Antibodies Viral; Carcinoma Hepatocellular; Cohort Studies; Female; Hepatitis B Core Antigens; Hepatitis B virus; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Risk Factors; GastroenterologyHepatocellular carcinomaHCVFemaleAdultmedicine.medical_specialtyHepatitis B virusCarcinoma Hepatocellularblood/pathology/virologyAntibodiesbloodblood/complications/pathologyInternal medicinemedicineHumansIn patientHEPATOCELLULAR CARCINOMAHEPATOCELLULAR CARCINOMA; HCV; HBV; CIRRHOSIS; HBV HCV COINFECTIONRetrospective StudiesHepatologybusiness.industryCarcinomaCancerHepatocellularmedicine.diseasedigestive system diseasesblood/etiology/pathologybusiness
researchProduct